Atypische Neuroleptika: Compliance und Lebensqualität

  • D. Naber
  • M. Lambert
Conference paper

Zusammenfassung

Seit der Entdeckung der neuroleptischen Wirkung des Chlorpromazins durch Delay und Deniker im Jahre 1952 sind die Neuroleptika von besonderer Bedeutung in der Behandlung schizophrener Patienten, der Nutzen ist sowohl bei akuten Psychosen wie auch in der Langzeitbehandlung bzw. in der Rezidivprophylaxe unbestritten. Ein wesentliches Problem, insbesondere in der Langzeitbehandlung, ist aber die geringe Bereitschaft der Patienten, die Neuroleptika regelmäßig einzunehmen. In zahlreichen Studien waren nur 30–40 % der Patienten compliant, für lange Zeit galt die mangelnde Einsicht in die Krankheit und in die Notwendigkeit einer medikamentösen Therapie als primärer Grund für diese niedrige Compliance. Neuere Studien hingegen deuten an, daß neben der Beziehung zwischen Arzt und Patient die subjektive Wirkung der Neuroleptika sowie objektive Nebenwirkungen für die Compliance von besonderer Bedeutung sind (27,79). So zeigte schon die frühe Untersuchung von van Putten (72) eine signifikante Beziehung zwischen motorischen Nebenwirkungen, insbesondere der subjektiv sehr quälenden Akathisie und der geringen Bereitschaft, langfristig Neuroleptika einzunehmen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Allison DB, Mentore JL, Heo M, Weiden P, Cappelleri J, Chandler LP (1998) Weight gain associated with conventional and newer antipsychotics: a meta-analysis. Abstract, Wed-P47. 9th Congress of Association of European Psychiatrists, Copenhagen, DenmarkGoogle Scholar
  2. 2.
    Awad A (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19: 609–618PubMedGoogle Scholar
  3. 3.
    Awad A, Hogan T (1994) Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 89 (Suppl. 380): 27–32CrossRefGoogle Scholar
  4. 4.
    Awad A, Voruganti L, Heslegrave R (1995) The aims of antipsychotic medications. What are they and are they being achieved CNS Drugs 4: 8–16CrossRefGoogle Scholar
  5. 5.
    Ayuso-Gutiérrez J, Barcia D, Herraiz M, Fernández A (1996) Quality of life in schizophrenic patients treated with risperidone. Poster of the 149th Annual Meeting of the APA, New York: NR 559Google Scholar
  6. 6.
    Bandelow B, Müller P, Frick U (1992) Depressive syndroms in schizophrenic patients under neuroleptic therapy. European Archives of Psychiatry and Clinical Neuroscience 141:291–295CrossRefGoogle Scholar
  7. 7.
    Bobes J, Gutiérrez M, Gibert J, González MP, Herraiz L, Fernández A (1998) Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry 13:158–163PubMedCrossRefGoogle Scholar
  8. 8.
    Boumans C, de Mooji K, Pam K (1994) Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia Schizopr Bull 20: 339–344Google Scholar
  9. 9.
    Buis W (1995) Patients’ opinions concerning side effects of depot neuroleptics (Letter). Am J Psychiatry 149: 844–845Google Scholar
  10. 10.
    Chiles J, Miller A, Crismon L, Rush J, Krasnoff A, Shon S (1999) The Texas Medication Algorithm Project: Development and Implementation of the Schizophrenia Algorithm. Psychiatric Services 50:69–74PubMedGoogle Scholar
  11. 11.
    Colonna L,Turjanski S,Dondey-Nouvel L (1998) Amisulpride — long-term efficacy and safety. European Psychiatry 13 (Suppl. 4): 309CrossRefGoogle Scholar
  12. 12.
    Daniel D,Wozniak P,Mack R,McCarthy B,Sertindole Study Group (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacology Bull 34 (1): 61–69Google Scholar
  13. 13.
    Davis J, Janicak P, Singla A, Sharma R (1993) Maintenance antipsychotic medication. In: Barnes T (Ed) Antipsychotic Drugs and Their Side Effects (pp. 183–203). New York, NY: Academic PressGoogle Scholar
  14. 14.
    Del Campo E, Carr C, Correa E (1983) Rehospitalized schizophrenics: What they report about illness, treatment and compliance. J Psychosocial Nursing Mental Health Serv 21:29–33Google Scholar
  15. 15.
    Duke PJ, Pantelis C, Barnes TR (1994) South Westminster schizophrenia survey: alcohol use and its relationships to symptoms, tardive dyskinesia, and illness onset. Br J Psychiatry 164: 630–636PubMedCrossRefGoogle Scholar
  16. 16.
    Emerich D, Sanberg P (1991) Neuroleptic dysphoria. Biol Psychiatry 29: 201–203PubMedCrossRefGoogle Scholar
  17. 17.
    Fleurot O,Bech P,Turjanski S (1997) Amisulpride versus risperidone in the treatment of acute schizophrenia. Biol Psychiatry 42:194–202CrossRefGoogle Scholar
  18. 18.
    Franz M (1997) Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170:422–425PubMedCrossRefGoogle Scholar
  19. 19.
    Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzker A, Tegeler J (1993) Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse. Br J Psychiatry 163 (Suppl. 21): 8–12Google Scholar
  20. 20.
    Hamilton S, Revicki D, Genduso L, Tollefson G, Edgell E (1998a) Costs of Olanzapine treatment compared with Haloperidol for schizophrenia: Results from a randomized clinical trial. Am Psychiatric Ass, Annual Meeting TorontoGoogle Scholar
  21. 21.
    Hamilton S, Revicki D, Genduso L, Beaslex C (1998b) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double blind trial. Neuropsychopharmacology 18:41–49PubMedCrossRefGoogle Scholar
  22. 22.
    Heinrich K (1967) Zur Bedeutung des postremissiven Erschöpfungs-Syndroms für die Rehabilitation Schizophrener. Nervenarzt 38:487–491PubMedGoogle Scholar
  23. 23.
    Heinrich D, Hanlon T, Carpenter WT jr (1984) The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388–398Google Scholar
  24. 24.
    Helmchen H, Hippius H (1969) Pharmakogene Depressionen. In: Hippius H, Selbach H (eds) Das Depressive Syndrom. Schattauer-Verlag Stuttgart, S 443–448Google Scholar
  25. 25.
    Hippius H, Stille G (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatrie 4: 182–191CrossRefGoogle Scholar
  26. 26.
    Hirsch S, Puri BK (1993) Clozapine: progress in treating refractory schizophrenia. Br Med J 306:1427–1428CrossRefGoogle Scholar
  27. 27.
    Hogan T, Awad A, Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 13:177–183PubMedCrossRefGoogle Scholar
  28. 28.
    House A, Bostock J, Cooper J (1987) Depressive syndromes in the Year following onset of a first schizophrenic illness. Br J Psychiatry 151: 773–9PubMedCrossRefGoogle Scholar
  29. 29.
    Jaeger J, Bitter I, Czobor P, Volavka J (1990) The measurement of subjective experience in schizophrenia: the subjective deficit syndrom scale. Compr Psychiatry 31: 261–226CrossRefGoogle Scholar
  30. 30.
    Johnston D (1985) Studies of depressive symptoms in schizophrenia. The prevalence of depression and ist possible causes. Br J Psychiatry 139: 89–101CrossRefGoogle Scholar
  31. 31.
    Kane J, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 8: 52–56CrossRefGoogle Scholar
  32. 32.
    Katschnig H (1998) Zyprexa in der Praxis: Hält es, was es verspricht Ergebnisse einer Anwendungsbeobachtung bei 221 Patienten niedergelassener Psychiater. Jatros Neurologie Psychiatrie 5: 40–42Google Scholar
  33. 33.
    Kissling W (1992) Neuroleptische Rezidivprophylaxe — eine verpaßte Chance In: Rifkin A, Osterheider M (Hrsg) Schizophrenie — aktuelle Trends und Behandlungsstrategien. Springer, Berlin, Heidelberg, S 83–91CrossRefGoogle Scholar
  34. 34.
    Knights A, Hirsch S (1981) Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38: 806–811PubMedCrossRefGoogle Scholar
  35. 35.
    Lader M (1993) Neuroleptic induced deficit syndrome: old problem, new challenge. J Psychopharmacol 7: 392–393PubMedCrossRefGoogle Scholar
  36. 36.
    Lambert M, Holzbach R, Haasen C, Postel N, Moritz S, Krausz M, Naber D (1998) The atypical antipsychotic medication Olanzapine — results of a clinical acute phase study. Kongress der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Essen, 17.–20. JuniGoogle Scholar
  37. 37.
    Lambert M, Haasen C, Naber D (1999) Pharmakotherapie schizophrener Erkrankungen — der aktuelle Stand. In: Hartwich P, Pflug B (Hrsg) Schizophrenien — Wege der Behandlung, S 95–123Google Scholar
  38. 38.
    Lambert M, Naber D (in Druck, a) Amisulprid (Solian®) — ein atypisches Antipsychotikum in der Behandlung schizophrener Erkrankungen. Fundamenta PsychiatricaGoogle Scholar
  39. 39.
    Lambert M, Perro C, Holzbach R, Krausz M, Naber D (in Druck, b). Olanzapin (Zyprexa®) — ein atypisches Antipsychotikum in der Behandlung schizophrener Erkrankungen. PsychopharmakotherapieGoogle Scholar
  40. 40.
    Lambert M, Pajonk F, Moritz S, Naber D (in Vorbereitung) Subjektive Befindlichkeit unter den atypischen Neuroleptika Clozapin, Risperidon und OlanzapinGoogle Scholar
  41. 41.
    Liddle P, Barnes T (1988) The subjecitve experience of deficits in schizophrenia. Comp Psychiatry 29:157–164CrossRefGoogle Scholar
  42. 42.
    Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of Clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 151:1744–1752PubMedGoogle Scholar
  43. 43.
    Loo H, Poirier-Littre M-F, Theron M, Rein W, Fleurot (1997) Amisulpride in the mediumterm treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22PubMedCrossRefGoogle Scholar
  44. 44.
    Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M (1982) Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Arch Gen Psychiatry 39 (2): 197–203PubMedCrossRefGoogle Scholar
  45. 45.
    Marder S, Mebane A, Chien C-P,Winsdale W, Swann E, Van Putten T (1983) A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 140: 470–472PubMedGoogle Scholar
  46. 46.
    Meltzer H, Burnett S, Bastani B, Ramirez L (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 41: 892–897Google Scholar
  47. 47.
    Möller HJ, von Zerssen D (1981) Depressive Symptomatik im stationären Behandlungsverlauf von 280 schizophrenen Patienten. Pharmacol Psychiatry 14:172–179Google Scholar
  48. 48.
    Möller HJ, Boyer P, Fleurot O, Rein W (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132:396–401PubMedCrossRefGoogle Scholar
  49. 49.
    zitiert nach Montgomery S.A. Mood and related symptoms in schizophrenia. Asia Pacific Regional Neuroscience Conference. 11.–14. February, 1999, Penang, MalaysiaGoogle Scholar
  50. 50.
    Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, compliance and other clinical variables. Int Clin Psychopharmacol 10 (Suppl.3): 133–138PubMedCrossRefGoogle Scholar
  51. 51.
    Naber D, Hippius H (1994) Indikation, Wirksamkeit und Verträglichkeit von Clozapin. Klinische Erfahrungen bei 1058 stationären Behandlungen. In: Naber D, Müller-Spahn F (Hrsg) Clozapin — Pharmakologie und Klinik eines atypischen Neuroleptikums. Neuere Aspekte der klinischen Praxis. Springer, Berlin, Heidelberg, New York, Tokyo, S 91–101CrossRefGoogle Scholar
  52. 52.
    Naber D, Lambert M (1998) Sertindole decreases hospitalisation and improves the quality of life of schizophrenic patients. International Journal of Psychiatry in Clinical practice 2 (Suppl. 2): 73–77Google Scholar
  53. 53.
    Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical Management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 (Suppl. 17): 54–59Google Scholar
  54. 54.
    Peacock K, Gerlach J (1994) Clozapine treatment in Denmark: Concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 55:44–49PubMedGoogle Scholar
  55. 55.
    Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F (1996) A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial. Psychopharmacol Bull 32:81–87PubMedGoogle Scholar
  56. 56.
    Peuskens J, the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726PubMedCrossRefGoogle Scholar
  57. 57.
    Pristach C, Smith C (1990) Medicationcompliance and substance among schizophrenic patients. Hosp Commun Psychiatry 41:1345–1348Google Scholar
  58. 58.
    Puech A, Fleurot O, Rein W (1998) Amisulpride, an atypical antipsychotic in the treatment of acute episodes of schizophrenia: a dose-range finding study. Acta Psychiatr Scand 98: 65–72PubMedCrossRefGoogle Scholar
  59. 59.
    Rein W, Fleurot O, Turjanski S (1998) Amisulpride improves affective symptoms in acute schizophrenia. European Psychiatry 13 (Suppl. 4): 309CrossRefGoogle Scholar
  60. 60.
    Rosenheck R, Cramer J, Xu W, Thomas J, Hernderson W, Frisman L, Fye C, Charney D (1997) A comparison of clozapine and haloperidol in hospitalizend patients with refractory schizophrenia. N Engl J Med 337: 809–815PubMedCrossRefGoogle Scholar
  61. 61.
    Safferman AZ, Lieberman JA, Pollack S, Kane JM (1993) Akathisia and clozapine treatment. J Clin Psychopharmacol 13: 286–287PubMedCrossRefGoogle Scholar
  62. 62.
    Salize H-J, Rössler W, Reinhard I (1996) Kostenermittlung in einem fragmentierten psychiatrischen Versorgungssystem. Gesundheitswesen 58 (Sonderausgabe): 10–17PubMedGoogle Scholar
  63. 63.
    Selten J, Sijben N, van den Bosch R, Omloo-Vissen J, Warmerdam H (1993) The subjective experience of negative symptoms: a self-rating scale. Comp Psychiatry 34:192–197CrossRefGoogle Scholar
  64. 64.
    Tollefson GD, Beasley CM et al. (1997a) Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaboration study. Am J Psychiatry 154:457–465PubMedGoogle Scholar
  65. 65.
    Tollefson GD, Sanger T, Todd M (1997b) Negative Symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trail with Olanzapine. Am J Psychiatry 154: 466–474PubMedGoogle Scholar
  66. 66.
    Tollefson GD, Sanger T, Todd M (1997c) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with Olanzapine or Haloperidol. Am J Psychiatry 154: 1248–1254PubMedGoogle Scholar
  67. 67.
    Tollefson G, Sanger T, Beasley C (1997d) The course of primary and secondary negative symptoms in a controlled trial with Olanzapine. Focus on Schizophrenia, Psychiatry Global Medical Conference, IndianapolisGoogle Scholar
  68. 68.
    Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998) Depressive signs and symptoms in schizophrenia — a prospective blinded trial of olanzapine and haloperidol. Archives of Gen Psychiatry 55: 250–258CrossRefGoogle Scholar
  69. 69.
    Tran P, Hamilton SH, Kuntz AJ et al. (1997a) Double-blind comparison of Olanzapine versus risperidon in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407–418PubMedCrossRefGoogle Scholar
  70. 70.
    Tran P, Delva M, Tollefson GD (1997b) Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58 (5):205–211PubMedCrossRefGoogle Scholar
  71. 71.
    Tuynman-Qua H, de Roos V, Duivenvoorden H, van Meer R (1998) Subjective experience of patients on olanzapine in comparison to other antipsychotics. Abstr Wed-P76, 9th Congress of Association of European Psychiatrists. Copenhagen, 20–24 SeptemberGoogle Scholar
  72. 72.
    Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs Arch Gen Psychiatry 31: 67–72PubMedCrossRefGoogle Scholar
  73. 73.
    Van Putten T, May T (1978) Akinetic depression: in schizophrenia. Arch Gen Psychiatry 35: 1101–1107PubMedCrossRefGoogle Scholar
  74. 74.
    Van Putten T, May P, Marder S, Wittmann L (1981) Subjective response to antpsychotic drugs. Arch Gen Psychiatry 38:187–190PubMedCrossRefGoogle Scholar
  75. 75.
    Van Putten T, May P, Marder S (1984) Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036–1039PubMedCrossRefGoogle Scholar
  76. 76.
    Wetzel H, Gründer G, Hillert A et al. (1998) Amisulpride versus flupentixol in schizophrenia with predominatly positive symtomatology. Psychopharmacol 137: 223–232CrossRefGoogle Scholar
  77. 77.
    Wise R (1991) Neuroleptic-induced anhedonia. Recent studies. In: Tamminga C, Schulz S (eds) Advances in Neuropsychiatry and Psychopharmacology. Schizophrenia Research 1: 323–331Google Scholar
  78. 78.
    Wyatt R (1992) Neuroleptics and natural course of schizophrenia. Schizophr Bull 17:325–351Google Scholar
  79. 79.
    Young J, Zonana H, Shepler L (1986) Medication noncompliance in schizophrenia: Codification and update. Bull Am Acad Psychiatry Law 14:105–122PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1999

Authors and Affiliations

  • D. Naber
    • 1
  • M. Lambert
  1. 1.Klinik für Psychiatrie und PsychotherapieUniversität HamburgHamburgDeutschland

Personalised recommendations